MedTrace Logo

A Study of LNK01001 Capsule in Patients With Moderate to Severe Atopic Dermatitis

NCT06085521 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2023-10-27

No results posted yet for this study

Summary

Participants who meet eligibility criteria will be randomized in a 1:1:1 ratio to receive a twice daily oral LNK01001 dose A or LNK01001 dose B or matching placebo for 12 weeks.

Conditions

Interventions

DRUG

LNK01001 Dose A

Capsules taken orally

DRUG

LNK01001 Dose B

Capsules taken orally

DRUG

placebo

Capsules taken orally

Sponsors & Collaborators

  • Lynk Pharmaceuticals Co., Ltd

    lead INDUSTRY

Principal Investigators

  • Jianzhong Zhang · Peking University People's Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-26
Primary Completion
2023-06-14
Completion
2023-06-14

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06085521 on ClinicalTrials.gov